Cargando…

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status

Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of com...

Descripción completa

Detalles Bibliográficos
Autores principales: Casale, Thomas B., Gimenez-Arnau, Ana Maria, Bernstein, Jonathan A., Holden, Michael, Zuberbier, Torsten, Maurer, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613187/
https://www.ncbi.nlm.nih.gov/pubmed/37776480
http://dx.doi.org/10.1007/s13555-023-01040-9
_version_ 1785128775302774784
author Casale, Thomas B.
Gimenez-Arnau, Ana Maria
Bernstein, Jonathan A.
Holden, Michael
Zuberbier, Torsten
Maurer, Marcus
author_facet Casale, Thomas B.
Gimenez-Arnau, Ana Maria
Bernstein, Jonathan A.
Holden, Michael
Zuberbier, Torsten
Maurer, Marcus
author_sort Casale, Thomas B.
collection PubMed
description Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.
format Online
Article
Text
id pubmed-10613187
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106131872023-10-30 Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status Casale, Thomas B. Gimenez-Arnau, Ana Maria Bernstein, Jonathan A. Holden, Michael Zuberbier, Torsten Maurer, Marcus Dermatol Ther (Heidelb) Review Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients. Springer Healthcare 2023-09-30 /pmc/articles/PMC10613187/ /pubmed/37776480 http://dx.doi.org/10.1007/s13555-023-01040-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Casale, Thomas B.
Gimenez-Arnau, Ana Maria
Bernstein, Jonathan A.
Holden, Michael
Zuberbier, Torsten
Maurer, Marcus
Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title_full Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title_fullStr Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title_full_unstemmed Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title_short Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
title_sort omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613187/
https://www.ncbi.nlm.nih.gov/pubmed/37776480
http://dx.doi.org/10.1007/s13555-023-01040-9
work_keys_str_mv AT casalethomasb omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus
AT gimenezarnauanamaria omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus
AT bernsteinjonathana omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus
AT holdenmichael omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus
AT zuberbiertorsten omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus
AT maurermarcus omalizumabforpatientswithchronicspontaneousurticariaanarrativereviewofcurrentstatus